Myocardial Ischemia

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

3100%

+ 30 programs with unclassified modality

Competitive Landscape

22 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

PfizerNEW YORK, NY

2 programs

AmlodipinePhase 4Small Molecule

Intensive medical therapyPhase 3

Kite PharmaCA - El Segundo

2 programs

RanolazinePhase 41 trial

RanolazinePhase 31 trial

Active Trials

NCT00099788Completed6,560Est. Feb 2007

NCT02423265Withdrawn0Est. Mar 2017

ViatrisCANONSBURG, PA

1 program

AmlodipinePhase 4Small Molecule1 trial

Active Trials

NCT00143195Completed200Est. Jan 2005

AbbottABBOTT PARK, IL

3 programs

Core size Xience PrimePhase 31 trial

ABSORB BVSN/A1 trial

Active Trials

NCT01023789Completed812Est. Oct 2016

NCT02928198Unknown3Est. Mar 2020

NCT00916370Completed525Est. Feb 2014

AstellasChina - Shenyang

2 programs

Intensive medical therapyPhase 3

RegadenosonPhase 21 trial

Active Trials

NCT01655043Completed20Est. Feb 2014

AstraZenecaCAMBRIDGE, United Kingdom

2 programs

Intensive medical therapyPhase 3

Coronary stentingPhase 2/31 trial

Active Trials

NCT02701140Completed58Est. Nov 2020

AmgenTHOUSAND OAKS, CA

1 program

Intensive medical therapyPhase 3

Integrated BiosciencesCA - San Carlos

1 program

Intensive medical therapyPhase 31 trial

Active Trials

NCT00007657Completed3,260Est. Jun 2006

MSDIreland - Ballydine

1 program

Intensive medical therapyPhase 3

Sharp TherapeuticsPA - Pittsburgh

1 program

Intensive medical therapyPhase 3

Lisata TherapeuticsNJ - Basking Ridge

2 programs

CLBS14Phase 21 trial

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)N/A1 trial

Active Trials

NCT00545610Completed150Est. Jun 2010

NCT00300053Completed321Est. Mar 2009

Martin PharmaceuticalsNY - New York

1 program

Heme arginate 3mg/kgPhase 21 trial

Active Trials

NCT02314780Completed31Est. Jun 2017

HelixmithKorea - Seoul

1 program

VM202Phase 1/21 trial

Active Trials

NCT01002495Withdrawn0Est. Jan 2016

CuoripsJapan - Tokyo

1 program

HumanPhase 11 trial

Active Trials

NCT04696328Unknown10Est. May 2023

Oregon TherapeuticsFrance - Paris

1 program

SonazoidPhase 11 trial

Active Trials

NCT03009266Unknown40Est. Dec 2019

BayerLEVERKUSEN, Germany

2 programs

Myocardial CT perfusionN/A1 trial

Stress cardiac magnetic resonanceN/A1 trial

Active Trials

NCT02161081Completed120Est. Jul 2014

NCT03192891Completed2,349Est. Nov 2019

GE HealthCare

2 programs

RegadenosonPHASE_1_21 trial

Intensive medical therapyPHASE_3

Active Trials

NCT04604782Recruiting54Est. Dec 2026

SanofiPARIS, France

2 programs

Intensive medical therapyPHASE_3

RamiprilPHASE_3Small Molecule1 trial

Active Trials

NCT00268619Completed

Gilead SciencesFOSTER CITY, CA

2 programs

RanolazinePHASE_3

RanolazinePHASE_4

Colorado TherapeuticsCO - Louisville

1 program

Day LightN/A1 trial

Active Trials

NCT03822949Recruiting70Est. Jul 2026

REVA MedicalCA - San Diego

1 program

ReZolve StentN/A1 trial

Active Trials

NCT01262703Completed49Est. Dec 2018

Bristol Myers SquibbPRINCETON, NJ

1 program

Intensive medical therapyPHASE_3

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Kite PharmaRanolazine

ViatrisAmlodipine

AbbottCore size Xience Prime

Kite PharmaRanolazine

SanofiRamipril

Integrated BiosciencesIntensive medical therapy

AstraZenecaCoronary stenting

Martin PharmaceuticalsHeme arginate 3mg/kg

AstellasRegadenoson

Lisata TherapeuticsCLBS14

GE HealthCareRegadenoson

HelixmithVM202

CuoripsHuman

Oregon TherapeuticsSonazoid

Colorado TherapeuticsDay Light

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 14,632 patients across 21 trials

NCT02423265 Kite PharmaRanolazine

Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries

Start: Jun 2015Est. completion: Mar 20170

Phase 4Withdrawn

NCT00143195 ViatrisAmlodipine

Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina

Start: Apr 2001Est. completion: Jan 2005200 patients

Phase 4Completed

NCT00916370 AbbottCore size Xience Prime

SPIRIT PRIME Clinical Trial

Start: Jun 2009Est. completion: Feb 2014525 patients

Phase 3Completed

NCT00099788 Kite PharmaRanolazine

Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

Start: Oct 2004Est. completion: Feb 20076,560 patients

Phase 3Completed

NCT00268619 SanofiRamipril

FOCUS:Focus On Coronary Unstable Syndromes

Start: Jun 2004

Phase 3Completed

NCT00007657 Integrated BiosciencesIntensive medical therapy

Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation

Start: Dec 1998Est. completion: Jun 20063,260 patients

Phase 3Completed

NCT02701140 AstraZenecaCoronary stenting

Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease

Start: Jun 2016Est. completion: Nov 202058 patients

Phase 2/3Completed

NCT02314780 Martin PharmaceuticalsHeme arginate 3mg/kg

The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart

Start: Mar 2015Est. completion: Jun 201731 patients

Phase 2Completed

NCT01655043 AstellasRegadenoson

Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI

Start: Sep 2012Est. completion: Feb 201420 patients

Phase 2Completed

NCT00300053 Lisata TherapeuticsCLBS14

ACT34-CMI -- Adult Autologous CD34+ Cells

Start: Apr 2006Est. completion: Mar 2009321 patients

Phase 2Completed

NCT04604782 GE HealthCareRegadenoson

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

Start: May 2021Est. completion: Dec 202654 patients

Phase 1/2Recruiting

NCT01002495 HelixmithVM202

Gene Therapy for the Treatment of Chronic Stable Angina

Start: Mar 2015Est. completion: Jan 20160

Phase 1/2Withdrawn

NCT04696328 CuoripsHuman

Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic Cardiomyopathy

Start: Dec 2019Est. completion: May 202310 patients

Phase 1Unknown

NCT03009266 Oregon TherapeuticsSonazoid

Ischemic Memory Imaging With Myocardial Contrast Echocardiography

Start: Jul 2018Est. completion: Dec 201940 patients

Phase 1Unknown

NCT03822949 Colorado TherapeuticsDay Light

Bright Light Exposure in Surgical Patients

Start: Jul 2019Est. completion: Jul 202670 patients

N/ARecruiting

NCT03192891 BayerStress cardiac magnetic resonance

Stress CMR Perfusion Imaging in the United States (SPINS) Study

Start: Dec 2016Est. completion: Nov 20192,349 patients

N/ACompleted

NCT02928198 AbbottABSORB BVS

Bifurcation ABSORB OCT Trial

Start: Jun 2016Est. completion: Mar 20203 patients

N/AUnknown

NCT02161081 BayerMyocardial CT perfusion

A Study on Improved Dynamic Myocardial Perfusion With Less Effective Radiation Dose in CT (SIMPLE CT)

Start: Jan 2012Est. completion: Jul 2014120 patients

N/ACompleted

NCT01262703 REVA MedicalReZolve Stent

Safety Study of a Bioresorbable Coronary Stent

Start: Dec 2011Est. completion: Dec 201849 patients

N/ACompleted

NCT01023789 AbbottABSORB BVS

ABSORB EXTEND Clinical Investigation

Start: Jan 2010Est. completion: Oct 2016812 patients

N/ACompleted

NCT00545610 Lisata TherapeuticsACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

Start: Oct 2007Est. completion: Jun 2010150 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

9 late-stage (Phase 3) programs, potential near-term approvals

2 actively recruiting trials targeting 14,632 patients

24 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.